Selpercatinib’s expedited approval in 2020 has provided another treatment option for patients with metastatic RET fusion-positive NSCLC and metastatic RET mutant medullary thyroid cancers [84,85]. This evidence concerns the gene RET and non-small cell lung carcinoma.